FOXP1 inhibits cell growth and attenuates tumorigenicity of neuroblastoma

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Ackermann, Sandra ^a   Kocak, Hayriye ^a   Hero, Barbara ^a   Ehemann, Volker ^b   Kahlert, Yvonne ^a   Oberthuer, André ^a   Roels, Frederik ^a   Theißen, Jessica ^a   Odenthal, Margarete ^a   Berthold, Frank ^a   Fischer, Matthias ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Cell proliferation; Disease progression; FoxP1; Neuroblastoma; Tumor suppressor

Indexed keywords

MESSENGER RNA; FORKHEAD TRANSCRIPTION FACTOR; FOXP1 PROTEIN, HUMAN; REPRESSOR PROTEIN; TUMOR MARKER;

ADOLESCENT; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER PROGNOSIS; CANCER STAGING; CARCINOGENICITY; CELL CYCLE ARREST; CELL PROLIFERATION; CELL VIABILITY; CHILD; COLONY FORMATION; CONTROLLED STUDY; DOWN REGULATION; FOXP1 GENE; GENE EXPRESSION; GENE IDENTIFICATION; GENE LOSS; GENE SILENCING; GENETIC ASSOCIATION; HETEROZYGOTE; HIGH RISK PATIENT; HUMAN; HUMAN CELL; HUMAN TISSUE; INFANT; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; NEUROBLASTOMA; NEUROBLASTOMA CELL LINE; PROMOTER REGION; TUMOR SUPPRESSOR GENE; CELL MOTION; CELL TRANSFORMATION; CLUSTER ANALYSIS; COMPARATIVE GENOMIC HYBRIDIZATION; DNA METHYLATION; GENE EXPRESSION PROFILING; GENETIC EPIGENESIS; GENETIC TRANSCRIPTION; GENETICS; MORTALITY; PATHOLOGY; PHENOTYPE; PRESCHOOL CHILD; PROGNOSIS; TUMOR CELL LINE;

APOPTOSIS; BIOMARKERS, TUMOR; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CHILD, PRESCHOOL; CLUSTER ANALYSIS; COMPARATIVE GENOMIC HYBRIDIZATION; DNA METHYLATION; EPIGENESIS, GENETIC; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION PROFILING; HUMANS; INFANT; NEOPLASM STAGING; NEUROBLASTOMA; PHENOTYPE; PROGNOSIS; PROMOTER REGIONS, GENETIC; REPRESSOR PROTEINS; TRANSCRIPTION, GENETIC;

EID: 84964315822     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-840     Document Type: Article

References (66)

1. Schwab M, Westermann F, Hero B, Berthold F: Neuroblastoma: biology and molecular and chromosomal pathology. Lancet Oncol 2003, 4(8):472-480.
2. Coldman AJ, Fryer CJ, Elwood JM, Sonley MJ: Neuroblastoma: influence of age at diagnosis, stage, tumor site, and sex on prognosis. Cancer 1980, 46(8):1896-1901.
3. Maris JM, Hogarty MD, Bagatell R, Cohn SL: Neuroblastoma. Lancet 2007, 369(9579):2106-2120.
4. Davidoff AM: Neuroblastoma. Semin Pediatr Surg 2012, 21(1):2-14.
5. Smith MA, Seibel NL, Altekruse SF, Ries LA, Melbert DL, O'Leary M, Smith FO, Reaman GH: Outcomes for children and adolescents with cancer: challenges for the twenty-first century. J Clin Oncol 2010, 28(15):2625-2634.
6. Lam EW, Brosens JJ, Gomes AR, Koo CY: Forkhead box proteins: tuning forks for transcriptional harmony. Nat Rev Cancer 2013, 13(7):482-495.
7. Kaufmann E, Knochel W: Five years on the wings of fork head. Mech Dev 1996, 57(1):3-20.
8. Koon HB, Ippolito GC, Banham AH, Tucker PW: FOXP1: a potential therapeutic target in cancer. Expert Opin Ther Targets 2007, 11(7):955-965.
9. Wang B, Weidenfeld J, Lu MM, Maika S, Kuziel WA, Morrisey EE, Tucker PW: Foxp1 regulates cardiac outflow tract, endocardial cushion morphogenesis and myocyte proliferation and maturation. Development 2004, 131(18):4477-4487.
10. Bates GJ, Fox SB, Han C, Launchbury R, Leek RD, Harris AL, Banham AH: Expression of the forkhead transcription factor FOXP1 is associated with that of estrogen receptor-beta in primary invasive breast carcinomas. Breast Cancer Res Treat 2008, 111(3):453-459.
11. Kim YS, Do Hwan J, Bae S, Bae DH, Ahn Shick W: Identification of differentially expressed genes using an annealing control primer system in stage III serous ovarian carcinoma. BMC Cancer 2010, 10:576.
12. Bieche I, Lidereau R: Genetic alterations in breast cancer. Genes Chromosomes Cancer 1995, 14(4):227-251.
13. Vandesompele J, Speleman F, Van Roy N, Laureys G, Brinskchmidt C, Christiansen H, Lampert F, Lastowska M, Bown N, Pearson A, Nicholson JC, Ross F, Combaret V, Delattre O, Feuerstein BG, Plantaz D: Multicentre analysis of patterns of DNA gains and losses in 204 neuroblastoma tumors: how many genetic subgroups are there? Med Pediatr Oncol 2001, 36(1):5-10.
14. Scaruffi P, Coco S, Cifuentes F, Albino D, Nair M, Defferrari R, Mazzocco K, Tonini GP: Identification and characterization of DNA imbalances in neuroblastoma by high-resolution oligonucleotide array comparative genomic hybridization. Cancer Genet Cytogenet 2007, 177(1):20-29.
15. Espinet B, Garcia-Herrera A, Gallardo F, Baro C, Salgado R, Servitje O, Estrach T, Colomo L, Romagosa V, Barranco C, Serrano S, Campo E, Pujol RM, Sole F: FOXP1 molecular cytogenetics and protein expression analyses in primary cutaneous large B cell lymphoma, leg-type. Histol Histopathol 2012, 26(2):213-221.
16. Zhang Y, Zhang S, Wang X, Liu J, Yang L, He S, Chen L, Huang J: Prognostic significance of FOXP1 as an oncogene in hepatocellular carcinoma. J Clin Pathol 2012, 65(6):528-533.
17. Oberthuer A, Juraeva D, Li L, Kahlert Y, Westermann F, Eils R, Berthold F, Shi L, Wolfinger RD, Fischer M, Brors B: Comparison of performance of one-color and two-color gene-expression analyses in predicting clinical endpoints of neuroblastoma patients. Pharmacogenomics J 2010, 10(4):258-266.
18. Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, De Bernardi B, Evans AE, Favrot M, Hedborg F, Kaneko M, Kemshead J, Lampert F, Lee REJ, Look T, Pearson ADJ, Philip T, Roald B, Sawada T, Seeger RC, Tsuchida Y, Voute PA: Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993, 11(8):1466-1477.
19. Kocak H, Ackermann S, Hero B, Kahlert Y, Oberthuer A, Juraeva D, Roels F, Theissen J, Westermann F, Deubzer H, Ehemann V, Brors B, Odenthal M, Berthold F, Fischer M: Hox-C9 activates the intrinsic pathway of apoptosis and is associated with spontaneous regression in neuroblastoma. Cell Death Dis 2013, 4:e586.
20. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP: Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005, 102(43):15545-15550.
21. Prukop T, Epplen DB, Nientiedt T, Wichert SP, Fledrich R, Stassart RM, Rossner MJ, Edgar JM, Werner HB, Nave KA, Sereda MW: Progesterone antagonist therapy in a Pelizaeus-Merzbacher mouse model. Am J Hum Genet 2014, 94(4):533-546.
22. Cohn SL, Pearson AD, London WB, Monclair T, Ambros PF, Brodeur GM, Faldum A, Hero B, Iehara T, Machin D, Mosseri V, Simon T, Garaventa A, Castel V, Matthay KK: The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol 2009, 27(2):289-297.
23. Fischer M, Bauer T, Oberthur A, Hero B, Theissen J, Ehrich M, Spitz R, Eils R, Westermann F, Brors B, Konig R, Berthold F: Integrated genomic profiling identifies two distinct molecular subtypes with divergent outcome in neuroblastoma with loss of chromosome 11q. Oncogene 2009, 29(6):865-875.
24. Spitz R, Oberthuer A, Zapatka M, Brors B, Hero B, Ernestus K, Oestreich J, Fischer M, Simon T, Berthold F: Oligonucleotide array-based comparative genomic hybridization (aCGH) of 90 neuroblastomas reveals aberration patterns closely associated with relapse pattern and outcome. Genes Chromosomes Cancer 2006, 45(12):1130-1142.
25. Ehrich M, Nelson MR, Stanssens P, Zabeau M, Liloglou T, Xinarianos G, Cantor CR, Field JK, van den Boom D: Quantitative high-throughput analysis of DNA methylation patterns by base-specific cleavage and mass spectrometry. Proc Natl Acad Sci U S A 2005, 102(44):15785-15790.
26. Oberthuer A, Berthold F, Warnat P, Hero B, Kahlert Y, Spitz R, Ernestus K, Konig R, Haas S, Eils R, Schwab M, Brors B, Westermann F, Fischer M: Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratification. J Clin Oncol 2006, 24(31):5070-5078.
27. Lausen B, Sauerbrei W, Schumacher M: Classification and regression trees (CART) used for the exploration of prognostic factors measured on different scales. In Computational Statistics 25th Conference on Statistical Computing Edn. Edited by Dirschedl P, Ostermann R. Heidelberg, Germany: Physica-Verlag; 1994:483-496.
28. Ackermann S, Goeser F, Schulte JH, Schramm A, Ehemann V, Hero B, Eggert A, Berthold F, Fischer M: Polo-like kinase 1 is a therapeutic target in highrisk neuroblastoma. Clin Cancer Res 2011, 17(4):731-741.
29. Ehemann V, Hashemi B, Lange A, Otto HF: Flow cytometric DNA analysis and chromosomal aberrations in malignant glioblastomas. Cancer Lett 1999, 138(1-2):101-106.
30. Benayoun BA, Caburet S, Veitia RA: Forkhead transcription factors: key players in health and disease. Trends Genet 2011, 27(6):224-232.
31. Hannenhalli S, Kaestner KH: The evolution of Fox genes and their role in development and disease. Nat Rev Genet 2009, 10(4):233-240.
32. Tang B, Becanovic K, Desplats PA, Spencer B, Hill AM, Connolly C, Masliah E, Leavitt BR, Thomas EA: Forkhead box protein p1 is a transcriptional repressor of immune signaling in the CNS: implications for transcriptional dysregulation in Huntington disease. Hum Mol Genet 2012, 21(14):3097-3111.
33. Krohn A, Seidel A, Burkhardt L, Bachmann F, Mader M, Grupp K, Eichenauer T, Becker A, Adam M, Graefen M, Huland H, Kurtz S, Steurer S, Tsourlakis MC, Minner S, Michl U, Schlomm T, Sauter G, Simon R, Sirma H: Recurrent deletion of 3p13 targets multiple tumor suppressor genes and defines a distinct subgroup of aggressive ERG fusion positive prostate cancers. J Pathol 2013, 231(1):130-141.
34. Hoeller S, Schneider A, Haralambieva E, Dirnhofer S, Tzankov A: FOXP1 protein overexpression is associated with inferior outcome in nodal diffuse large B-cell lymphomas with non-germinal centre phenotype, independent of gains and structural aberrations at 3p14.1. Histopathology 2010, 57(1):73-80.
35. Lenz G, Wright GW, Emre NC, Kohlhammer H, Dave SS, Davis RE, Carty S, Lam LT, Shaffer AL, Xiao W, Powell J, Rosenwald A, Ott G, Muller-Hermelink HK, Gascoyne RD, Connors JM, Campo E, Jaffe ES, Delabie J, Smeland EB, Rimsza LM, Fisher RI, Weisenburger DD, Chan WC, Staudt LM: Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci U S A 2008, 105(36):13520-13525.
36. Wlodarska I, Veyt E, De Paepe P, Vandenberghe P, Nooijen P, Theate I, Michaux L, Sagaert X, Marynen P, Hagemeijer A, De Wolf-Peeters C: FOXP1, a gene highly expressed in a subset of diffuse large B-cell lymphoma, is recurrently targeted by genomic aberrations. Leukemia 2005, 19(8):1299-1305.
37. Li D, Mei H, Qi M, Yang D, Zhao X, Xiang X, Pu J, Huang K, Zheng L, Tong Q: FOXD3 is a novel tumor suppressor that affects growth, invasion, metastasis and angiogenesis of neuroblastoma. Oncotarget 2013, 4(11):2021-2044.
38. Santo EE, Ebus ME, Koster J, Schulte JH, Lakeman A, van Sluis P, Vermeulen J, Gisselsson D, Ora I, Lindner S, Buckley PG, Stallings RL, Vandesompele J, Eggert A, Caron HN, Versteeg R, Molenaar JJ: Oncogenic activation of FOXR1 by 11q23 intrachromosomal deletion-fusions in neuroblastoma. Oncogene 2012, 31(12):1571-1581.
39. Wang Z, Park HJ, Carr JR, Chen YJ, Zheng Y, Li J, Tyner AL, Costa RH, Bagchi S, Raychaudhuri P: FoxM1 in tumorigenicity of the neuroblastoma cells and renewal of the neural progenitors. Cancer Res 2011, 71(12):4292-4302.
40. Obexer P, Hagenbuchner J, Unterkircher T, Sachsenmaier N, Seifarth C, Bock G, Porto V, Geiger K, Ausserlechner M: Repression of BIRC5/survivin by FOXO3/FKHRL1 sensitizes human neuroblastoma cells to DNA damage-induced apoptosis. Mol Biol Cell 2009, 20(7):2041-2048.
41. Xue L, Yue S, Zhang J: FOXP1 has a low expression in human gliomas and its overexpression inhibits proliferation, invasion and migration of human glioma U251 cells. Mol Med Rep 2014, 10(1):467-472.
42. Briet M, Schiffrin EL: Aldosterone: effects on the kidney and cardiovascular system. Nat Rev Nephrol 2010, 6(5):261-273.
43. Lamant L, de Reynies A, Duplantier MM, Rickman DS, Sabourdy F, Giuriato S, Brugieres L, Gaulard P, Espinos E, Delsol G: Gene-expression profiling of systemic anaplastic large-cell lymphoma reveals differences based on ALK status and two distinct morphologic ALK + subtypes. Blood 2007, 109(5):2156-2164.
44. Kim YM, Cho M: Activation of NADPH oxidase subunit NCF4 induces ROS-mediated EMT signaling in HeLa cells. Cell Signal 2014, 26(4):784-796.
45. Verhagen AM, Ekert PG, Pakusch M, Silke J, Connolly LM, Reid GE, Moritz RL, Simpson RJ, Vaux DL: Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell 2000, 102(1):43-53.
46. Bazenet CE, Mota MA, Rubin LL: The small GTP-binding protein Cdc42 is required for nerve growth factor withdrawal-induced neuronal death. Proc Natl Acad Sci U S A 1998, 95(7):3984-3989.
47. Raval A, Tanner SM, Byrd JC, Angerman EB, Perko JD, Chen SS, Hackanson B, Grever MR, Lucas DM, Matkovic JJ, Lin TS, Kipps TJ, Murray F, Weisenburger D, Sanger W, Lynch J, Watson P, Jansen M, Yoshinaga Y, Rosenquist R, de Jong PJ, Coggill P, Beck S, Lynch H, de la Chapelle A, Plass C: Downregulation of death-associated protein kinase 1 (DAPK1) in chronic lymphocytic leukemia. Cell 2007, 129(5):879-890.
48. Mao L, Ding J, Zha Y, Yang L, McCarthy BA, King W, Cui H, Ding HF: HOXC9 links cell-cycle exit and neuronal differentiation and is a prognostic marker in neuroblastoma. Cancer Res 2011, 71(12):4314-4324.
49. Zha Y, Ding E, Yang L, Mao L, Wang X, McCarthy BA, Huang S, Ding HF: Functional dissection of HOXD cluster genes in regulation of neuroblastoma cell proliferation and differentiation. PLoS One 2012, 7(8):e40728.
50. Soltani MH, Pichardo R, Song Z, Sangha N, Camacho F, Satyamoorthy K, Sangueza OP, Setaluri V: Microtubule-associated protein 2, a marker of neuronal differentiation, induces mitotic defects, inhibits growth of melanoma cells, and predicts metastatic potential of cutaneous melanoma. Am J Pathol 2005, 166(6):1841-1850.
51. Andersson G, Pahlman S, Parrow V, Johansson I, Hammerling U: Activation of the human NPY gene during neuroblastoma cell differentiation: induced transcriptional activities of AP-1 and AP-2. Cell Growth Differ 1994, 5(1):27-36.
52. Craig VJ, Cogliatti SB, Imig J, Renner C, Neuenschwander S, Rehrauer H, Schlapbach R, Dirnhofer S, Tzankov A, Muller A: Myc-mediated repression of microRNA-34a promotes high-grade transformation of B-cell lymphoma by dysregulation of FoxP1. Blood 2011, 117(23):6227-6236.
53. Buckley PG, Alcock L, Bryan K, Bray I, Schulte JH, Schramm A, Eggert A, Mestdagh P, De Preter K, Vandesompele J, Speleman F, Stallings RL: Chromosomal and microRNA expression patterns reveal biologically distinct subgroups of 11q- neuroblastoma. Clin Cancer Res 2010, 16(11):2971-2978.
54. Scaruffi P, Stigliani S, Moretti S, Coco S, De Vecchi C, Valdora F, Garaventa A, Bonassi S, Tonini GP: Transcribed-Ultra Conserved Region expression is associated with outcome in high-risk neuroblastoma. BMC Cancer 2009, 9:441.
55. Spitz R, Hero B, Ernestus K, Berthold F: Deletions in chromosome arms 3p and 11q are new prognostic markers in localized and 4 s neuroblastoma. Clin Cancer Res 2003, 9(1):52-58.
56. Molenaar JJ, Koster J, Zwijnenburg DA, van Sluis P, Valentijn LJ, van der Ploeg I, Hamdi M, van Nes J, Westerman BA, van Arkel J, Ebus ME, Haneveld F, Lakeman A, Schild L, Molenaar P, Stroeken P, van Noesel MM, Ora I, Santo EE, Caron HN, Westerhout EM, Versteeg R: Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes. Nature 2012, 483(7391):589-593.
57. Pugh TJ, Morozova O, Attiyeh EF, Asgharzadeh S, Wei JS, Auclair D, Carter SL, Cibulskis K, Hanna M, Kiezun A, Kim J, Lawrence MS, Lichenstein L, McKenna A, Pedamallu CS, Ramos AH, Shefler E, Sivachenko A, Sougnez C, Stewart C, Ally A, Birol I, Chiu R, Corbett RD, Hirst M, Jackman SD, Kamoh B, Khodabakshi AH, Krzywinski M, Lo A, et al: The genetic landscape of highrisk neuroblastoma. Nat Genet 2013, 45(3):279-284.
58. Katoh M, Igarashi M, Fukuda H, Nakagama H: Cancer genetics and genomics of human FOX family genes. Cancer Lett 2013, 328(2):198-206.
59. Shigekawa T, Ijichi N, Takayama S, Tsuda H, Ikeda K, Horie K, Osaki A, Saeki T, Inoue S: FOXP1 as a Potential ER Coregulator in Human Breast Cancer. Cancer Res 2009, 69(24):757S-757S.
60. van Boxtel R, Gomez-Puerto C, Mokry M, Eijkelenboom A, van der Vos KE, Nieuwenhuis EE, Burgering BM, Lam EW, Coffer PJ: FOXP1 acts through a negative feedback loop to suppress FOXO-induced apoptosis. Cell Death Differ 2013, 20(9):1219-1229.
61. Gabut M, Samavarchi-Tehrani P, Wang X, Slobodeniuc V, O'Hanlon D, Sung HK, Alvarez M, Talukder S, Pan Q, Mazzoni EO, Nedelec S, Wichterle H, Woltjen K, Hughes TR, Zandstra PW, Nagy A, Wrana JL, Blencowe BJ: An alternative splicing switch regulates embryonic stem cell pluripotency and reprogramming. Cell 2011, 147(1):132-146.
62. Quesada V, Conde L, Villamor N, Ordonez GR, Jares P, Bassaganyas L, Ramsay AJ, Bea S, Pinyol M, Martinez-Trillos A, Lopez-Guerra M, Colomer D, Navarro A, Baumann T, Aymerich M, Rozman M, Delgado J, Gine E, Hernandez JM, Gonzalez-DiazM, Puente DA, Velasco G, Freije JM, Tubio JM, Royo R, Gelpi JL, Orozco M, Pisano DG, Zamora J, Vazquez M, et al: Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat Genet 2012, 44(1):47-52.
63. Pajer P, Pecenka V, Kralova J, Karafiat V, Prukova D, Zemanova Z, Kodet R, Dvorak M: Identification of potential human oncogenes by mapping the common viral integration sites in avian nephroblastoma. Cancer Res 2006, 66(1):78-86.
64. Datta J, Kutay H, Nasser MW, Nuovo GJ, Wang B, Majumder S, Liu CG, Volinia S, Croce CM, Schmittgen TD, Ghoshal K, Jacob ST: Methylation mediated silencing of MicroRNA-1 gene and its role in hepatocellular carcinogenesis. Cancer Res 2008, 68(13):5049-5058.
65. Rao DS, O'Connell RM, Chaudhuri AA, Garcia-Flores Y, Geiger TL, Baltimore D: MicroRNA-34a perturbs B lymphocyte development by repressing the forkhead box transcription factor Foxp1. Immunity 2010, 33(1):48-59.
66. Streubel B, Vinatzer U, Lamprecht A, Raderer M, Chott A: T(3;14) (p14.1;q32) involving IGH and FOXP1 is a novel recurrent chromosomal aberration in MALT lymphoma. Leukemia 2005, 19(4):652-658.